Zydus Cadila gets USFDA nod for arthritis drug with 180-days exclusivity

INDIA – Drug firm Zydus Cadila has received final approval from the US health regulator to market Tofacitinib extended-release tablets, used to treat rheumatoid arthritis, in the American market. The company said it has received approval from the US Food and Drug Administration (USFDA) for the drug in 11 mg and 22 mg strengths. Zydus was the first abbreviated new drug application (ANDA) filer on Tofacitinib extended-release tablets 22 mg and thus holds 180-day exclusivity on this strength, the company said in a statement. Arthritis, or joint disease, is inflammation…

Read More